Dr. Kirk Pappan is the Director of Clinical Diagnostics at GeneCentric. Previously he led teams and programs at Owlstone Medical, Inc. and Metabolon leading to biomarker discovery and the development of diagnostic, precision medicine, and clinical metabolomics applications for metabolite biomarkers in areas of gut health, infectious diseases, inborn errors of metabolism, and undiagnosed disease. While at Metabolon, his technical leadership was pivotal for the development and launch of the clinical metabolomics CLIA LDTs, Meta IMD and Meta UDx. Dr. Pappan completed PhD and MBA degrees at Kansas State University before conducting post-doctoral research at Washington University focused on type 1 and 2 diabetes by the study of lipid mediated beta-cell dysfunction, ex vivo nutrient induced beta-cell proliferation prior to islet transplantation, and therapeutic stimulation of beta-cell replication.